Domainex Ltd., based in Cambridge UK, is a leading provider of integrated drug discovery services. As a result of the work carried out by Domainex during an in-house research programme to identify inhibitors of protein kinases TBK1 and IKK-epsilon, DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. The recent human ex-vivo data outlined below indicates this drug should be effective in the treatment of interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma.
PRESS RELEASE
New Study Reveals First Genetic Links in ME and Chronic Fatigue Syndrome Paving the Way for New Diagnostics and Drugs
PrecisionLife Reports 14 Genes Associated with ME/CFS at the M.E. Genetics Research Summit in Edinburgh
Life science and healthcare specialists – AMSBIO has launched a new set of dedicated webpages and content downloads detailing their extensive range of high quality GMP-compliant products and services.
WESTBROOK, Connecticut (USA) - The Lee Company is pleased to announce that it has acquired TTP Ventus Limited from TTP Group. Based near Cambridge, UK, TTP Ventus is an inventor and manufacturer of silent, compact micropumps and pump modules with unrivalled features, enabling cutting-edge innovation across the medical, life science, environmental, and industrial sectors. These products complement The Lee Company’s existing broad range of miniature fluid control components widely utilized across the same industries.
XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan. XenoTech specializes in ADME, DMPK and DDI testing of potential drug candidates.
Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel
Edinburgh and Cambridge, UK, 12 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes